Skip to main content

Table 2 The difference in Gal-3 levels according to different groups of patients

From: Role of galectin-3 in diagnosis and severity assessment of epicardial artery lesions in patients with suspected coronary artery disease

  

N

Mean

SD

t-test

Control group (0 – 1)

0

121

19,98

9,58

t = 9,075b

1

47

9,51

5,19

p = 0,000*

PCI – CABG

PCI

64

18,84

8,59

t = -1,402a

CABG

57

21,27

10,52

p = 0,164

Control group (1) – PCI

1

47

9,51

5,19

t = -6,607a

PCI

64

18,84

8,59

p = 0,000*

Control group (1) – CABG

1

47

9,51

5,19

t = -7,418b

CABG

57

21,27

10,52

p = 0,000*

Age

26 – 60

38

20,77

10,44

t = 0,610a

61 – 84

83

19,62

9,21

p = 0,543

Gender

1

66

19,72

9,95

t = -0,333a

2

55

20,30

9,20

p = 0,740

1VD [control group (0)]

0

78

20,91

10,71

t = 1,614b

1

43

18,31

6,91

p = 0,109

2VD [control group (0)]

0

97

20,54

9,82

t = 1,292a

1

25

17,73

8,38

p = 0,199

3VD [control group (0)]

0

90

17,75

7,11

t = -3,652b

1

31

26,46

12,61

p = 0,001*

LMCA [control group (0)]

0

98

20,25

9,25

t = 0,630b

1

24

18,85

11,05

p = 0,530

  1. T-test, aEqual variance assumed, bEqual variances not assumed, *statistically significant at p < 0,05; PCI percutaneous coronary intervention, CABG coronary artery bypass graft surgery, VD vessel disease